ERA-NET TRANSCAN-3: Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy

This call of TRANSCAN focuses on: Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy

The call has three specific aims, and proposals must cover at least one of the specific topics listed below:

Aim 1) Identification/validation of novel early diagnostic approaches

Aim 2) Identification/validation of novel therapeutic approaches

Aim 3) Development of novel drug delivery strategies

Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners, eligible for funding, coming from at least 3 different countries whose funders participate in the call.

Israeli applicants should contact Chief Scientist of the Ministry of Health (Dr. Irit Alon/ Dr. Liron Even- Faitelson) to review and approve submission prior to application. 

Pls. note that in most cases applicants may hold only one MOH grant at any given time. Please check eligibility.

MOH will award  2 grants. 

Funding: €140,000 total for Israeli partner + €20,000 for coordination
Duration: 3 years

Research Authority due date: 11.7.22

Pre proposal due date: 18.7.22
Full proposal due date:  15.12.22